US drugmakers turn to China for licensing deals

Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.Chinese biotechs often retain domestic rights and license their drugs overseas…